Mrs. Jessica Rae Engle, OCCUPATIONAL THERAPI Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 412-915-9062 |
Matthew Ceran, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3737 Lindberg Way, Weirton, WV 26062 Phone: 304-374-5137 |
Audrey Ellen Fisher, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 304-797-6496 |
Emalee Jean Hvizdak Occupational Therapist Medicare: Medicare Enrolled Practice Location: 134 Wilkins Ave, Weirton, WV 26062 Phone: 304-502-2455 |
Dana Chandler, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 304-797-6495 |
Mrs. Breanna Adkins, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2525 Pennsylvania Ave, Weirton, WV 26062 Phone: 304-723-4300 |
News Archive
Medical Properties Trust, Inc. announced today that the previously announced public offering of $200 million aggregate principal amount of senior notes due 2022 by its operating partnership, MPT Operating Partnership, L.P., a Delaware limited partnership, and MPT Finance Corporation, a Delaware corporation and wholly owned subsidiary of the Operating Partnership, priced today with a coupon of 6.375%, at an issue price of 100%.
A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Researchers at Thomas Jefferson University discovered that nearly half of coronary artery bypass patients are not taking statins and aspirin together when they are referred for diagnostic cardiac catheterization at least three years after their initial bypass. Their results are currently in press online in the American Journal of Cardiology.
Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.
› Verified 4 days ago